Compare EVTV & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVTV | ONCO |
|---|---|---|
| Founded | 2012 | 2018 |
| Country | United States | United States |
| Employees | 22 | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.6M | 2.3M |
| IPO Year | 2014 | 2021 |
| Metric | EVTV | ONCO |
|---|---|---|
| Price | $1.54 | $2.94 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 951.5K | 363.8K |
| Earning Date | 04-14-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 22.80 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,870,060.00 | $815,371.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.15 | $0.05 |
| 52 Week High | $5.07 | $7.65 |
| Indicator | EVTV | ONCO |
|---|---|---|
| Relative Strength Index (RSI) | 46.50 | 86.24 |
| Support Level | $1.30 | $2.63 |
| Resistance Level | $1.69 | $3.20 |
| Average True Range (ATR) | 0.22 | 0.22 |
| MACD | 0.03 | 0.29 |
| Stochastic Oscillator | 33.68 | 79.36 |
Envirotech Vehicles Inc is a provider of purpose-built zero-emission electric vehicles focused on reducing the total cost of vehicle ownership and helping fleet operators unlock the benefits of green technology. It recognizes revenue from the sales of zero-emission electric vehicles and vehicle maintenance and inspection services. The Company serves commercial and last-mile fleets, school districts, public and private transportation service companies and colleges and universities to meet the increasing demand for light to heavy-duty electric vehicles.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.